Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis-Reference-Cited by-同舟云学术

Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis

Published:2018-09 Issue:9 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Rancoita Paola M. V.¹,Cugnata Federica¹,Gibertoni Cruz Ana Luíza²,Borroni Emanuele³,Hoosdally Sarah J.²,Walker Timothy M.²,Grazian Clara²,Davies Timothy J.²,Peto Timothy E. A.²,Crook Derrick W.²,Fowler Philip W.²^ORCID,Cirillo Daniela M.³^ORCID,

Affiliation:

1. University Centre of Statistics in the Biomedical Sciences, Vita-Salute San Raffaele University, Milan, Italy

2. Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Headley Way, Oxford, United Kingdom

3. Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy

Abstract

The UKMYC5 plate is a 96-well microtiter plate designed by the CRyPTIC Consortium (Comprehensive Resistance Prediction for Tuberculosis: an International Consortium) to enable the measurement of MICs of 14 different antituberculosis (anti-TB) compounds for >30,000 clinical Mycobacterium tuberculosis isolates. Unlike the MYCOTB plate, on which the UKMYC5 plate is based, the UKMYC5 plate includes two new (bedaquiline and delamanid) and two repurposed (clofazimine and linezolid) compounds.

Funder

DH | National Institute for Health Research

Bill and Melinda Gates Foundation

Wellcome

RCUK | Medical Research Council

Newton Fund

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00344-18